169 related articles for article (PubMed ID: 36574921)
21. Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms.
Primadharsini PP; Nagashima S; Nishiyama T; Okamoto H
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896767
[TBL] [Abstract][Full Text] [Related]
22. Development of Recombinant Infectious Hepatitis E Virus Harboring the nanoKAZ Gene and Its Application in Drug Screening.
Primadharsini PP; Nagashima S; Nishiyama T; Takahashi M; Murata K; Okamoto H
J Virol; 2022 Mar; 96(6):e0190621. PubMed ID: 35107380
[TBL] [Abstract][Full Text] [Related]
23. Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients.
Cordts SE; Schneble L; Schnitzler P; Wenzel JJ; Vinke T; Rieger S; Fichtner A; Tönshoff B; Höcker B
Pediatr Nephrol; 2018 Jul; 33(7):1215-1225. PubMed ID: 29500631
[TBL] [Abstract][Full Text] [Related]
24. Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101.
Anang S; Kaushik N; Hingane S; Kumari A; Gupta J; Asthana S; Shalimar ; Nayak B; Ranjith-Kumar CT; Surjit M
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068652
[TBL] [Abstract][Full Text] [Related]
25. The lysine residues within the human ribosomal protein S17 sequence naturally inserted into the viral nonstructural protein of a unique strain of hepatitis E virus are important for enhanced virus replication.
Kenney SP; Meng XJ
J Virol; 2015 Apr; 89(7):3793-803. PubMed ID: 25609799
[TBL] [Abstract][Full Text] [Related]
26. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.
Wang Y; Zhou X; Debing Y; Chen K; Van Der Laan LJ; Neyts J; Janssen HL; Metselaar HJ; Peppelenbosch MP; Pan Q
Gastroenterology; 2014 Jun; 146(7):1775-83. PubMed ID: 24582714
[TBL] [Abstract][Full Text] [Related]
27. Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication.
Debing Y; Winton J; Neyts J; Dallmeier K
Antiviral Res; 2013 Oct; 100(1):98-101. PubMed ID: 23916729
[TBL] [Abstract][Full Text] [Related]
28. An ethanol extract of Lysimachia mauritiana exhibits inhibitory activity against hepatitis E virus genotype 3 replication.
Jin SE; Kim JE; Kim SY; Park BJ; Song YJ
J Microbiol; 2017 Dec; 55(12):984-988. PubMed ID: 29214492
[TBL] [Abstract][Full Text] [Related]
29. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication.
Wang W; Wang Y; Debing Y; Zhou X; Yin Y; Xu L; Herrera Carrillo E; Brandsma JH; Poot RA; Berkhout B; Neyts J; Peppelenbosch MP; Pan Q
Antiviral Res; 2017 Apr; 140():1-12. PubMed ID: 28077314
[TBL] [Abstract][Full Text] [Related]
30. Screening of novel drugs for inhibiting hepatitis E virus replication.
Nishiyama T; Kobayashi T; Jirintai S; Kii I; Nagashima S; Prathiwi Primadharsini P; Nishizawa T; Okamoto H
J Virol Methods; 2019 Aug; 270():1-11. PubMed ID: 31004661
[TBL] [Abstract][Full Text] [Related]
31. Update on hepatitis E virology: Implications for clinical practice.
Debing Y; Moradpour D; Neyts J; Gouttenoire J
J Hepatol; 2016 Jul; 65(1):200-212. PubMed ID: 26966047
[TBL] [Abstract][Full Text] [Related]
32. Course and treatment of chronic hepatitis E virus infection in lung transplant recipients.
Pischke S; Greer M; Hardtke S; Bremer B; Gisa A; Lehmann P; Haverich A; Welte T; Manns MP; Wedemeyer H; Gottlieb J;
Transpl Infect Dis; 2014 Apr; 16(2):333-9. PubMed ID: 24438577
[TBL] [Abstract][Full Text] [Related]
33. FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-κB-RIPK1-caspase axis.
Qu C; Li Y; Li Y; Yu P; Li P; Donkers JM; van de Graaf SFJ; de Man RA; Peppelenbosch MP; Pan Q
Antiviral Res; 2019 Oct; 170():104588. PubMed ID: 31415805
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients.
Friebus-Kardash J; Eisenberger U; Ackermann J; Kribben A; Witzke O; Wenzel J; Rohn H; Fiedler M
Transpl Infect Dis; 2019 Jun; 21(3):e13088. PubMed ID: 30929308
[TBL] [Abstract][Full Text] [Related]
35. The PRMT5/WDR77 complex restricts hepatitis E virus replication.
Ju X; Yu Y; Ren W; Dong L; Meng X; Deng H; Nan Y; Ding Q
PLoS Pathog; 2023 Jun; 19(6):e1011434. PubMed ID: 37276230
[TBL] [Abstract][Full Text] [Related]
36. ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.
Sooryanarain H; Rogers AJ; Cao D; Haac MER; Karpe YA; Meng XJ
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724761
[TBL] [Abstract][Full Text] [Related]
37. Two mutations in the ORF1 of genotype 1 hepatitis E virus enhance virus replication and may associate with fulminant hepatic failure.
Wang B; Tian D; Sooryanarain H; Mahsoub HM; Heffron CL; Hassebroek AM; Meng XJ
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2207503119. PubMed ID: 35969750
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of hepatitis E virus replication by peptide-conjugated morpholino oligomers.
Nan Y; Ma Z; Kannan H; Stein DA; Iversen PI; Meng XJ; Zhang YJ
Antiviral Res; 2015 Aug; 120():134-9. PubMed ID: 26086884
[TBL] [Abstract][Full Text] [Related]
39. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids.
Li P; Li Y; Wang Y; Liu J; Lavrijsen M; Li Y; Zhang R; Verstegen MMA; Wang Y; Li TC; Ma Z; Kainov DE; Bruno MJ; de Man RA; van der Laan LJW; Peppelenbosch MP; Pan Q
Sci Adv; 2022 Jan; 8(3):eabj5908. PubMed ID: 35044825
[TBL] [Abstract][Full Text] [Related]
40. High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection.
Liang Z; Shu J; He Q; Zhang F; Dai L; Wang L; Lu F; Wang L
Antiviral Res; 2022 Mar; 199():105274. PubMed ID: 35247472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
